OBJECTIVES:
- To detect antibodies against NF155, nodal neurofascins (NF140, NF186) and CNTN1 in Amyotrophic neuralgia patients from Switzerland (ICQ).
SAMPLES:
- For CNTN1: 21-2-0110, 21-2-0111, 21-2-0112, 21-2-0113, 21-2-0114, 21-2-638, 21-5-639, positive control.
- For NF140-186: 21-2-0110, 21-2-0111, 21-2-0112, 21-2-0113, 21-2-0114, 21-2-638, 21-5-639, positive control.
- For NF155: 21-2-0110, 21-2-0111, 21-2-0112, 21-2-0113, 21-2-0114, 21-2-638, 21-5-639, positive control.
ICC CNTN1:
Blocking solution: Rabbit serum in PBS.
- Patient’s sera diluted 1/100 in rabbit sèrum in PBS.
- Primary antibody: anti-CNTN1 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 (1/1000)
- Vectashield mounting medium.
ICC NF155/NF140/NF186:
Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 in 5% goat serum in PBS.
- Primary antibody: anti-NF diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 (1/1000).
- Vectashield mounting medium
RESULTS: All samples were negative, except the sample 21-5-639 (LCR) that was positive for CNTN1 and NF155.
